CN113645988A - 基于fms样酪氨酸激酶3配体(flt3l)的嵌合蛋白 - Google Patents

基于fms样酪氨酸激酶3配体(flt3l)的嵌合蛋白 Download PDF

Info

Publication number
CN113645988A
CN113645988A CN202080025812.5A CN202080025812A CN113645988A CN 113645988 A CN113645988 A CN 113645988A CN 202080025812 A CN202080025812 A CN 202080025812A CN 113645988 A CN113645988 A CN 113645988A
Authority
CN
China
Prior art keywords
chimeric protein
cancer
leu
seq
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080025812.5A
Other languages
English (en)
Chinese (zh)
Inventor
N·克雷
J·塔威尼尔
A·范帕里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Orinis Bioscience Co ltd
Original Assignee
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Orinis Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB, Orinis Bioscience Co ltd filed Critical Universiteit Gent
Publication of CN113645988A publication Critical patent/CN113645988A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080025812.5A 2019-03-28 2020-03-27 基于fms样酪氨酸激酶3配体(flt3l)的嵌合蛋白 Pending CN113645988A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825579P 2019-03-28 2019-03-28
US62/825,579 2019-03-28
PCT/US2020/025419 WO2020198659A1 (en) 2019-03-28 2020-03-27 Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins

Publications (1)

Publication Number Publication Date
CN113645988A true CN113645988A (zh) 2021-11-12

Family

ID=72608957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080025812.5A Pending CN113645988A (zh) 2019-03-28 2020-03-27 基于fms样酪氨酸激酶3配体(flt3l)的嵌合蛋白

Country Status (6)

Country Link
US (1) US20220185857A1 (https=)
EP (1) EP3946409A4 (https=)
JP (2) JP7749186B2 (https=)
CN (1) CN113645988A (https=)
CA (1) CA3133830A1 (https=)
WO (1) WO2020198659A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114606227A (zh) * 2022-02-22 2022-06-10 复旦大学 高精度腺嘌呤碱基编辑器及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
AU2024341598A1 (en) * 2023-09-12 2026-04-23 Heligenics Inc. Engineered interferon-beta proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017810A2 (en) * 1996-10-25 1998-04-30 G.D. Searle & Co. Multi-functional chimeric hematopoietic receptor agonists
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US20180360996A1 (en) * 2015-12-08 2018-12-20 University-Industry Foundation, Yonsei University ANTI-TUMOR COMPOSITION COMPRISING GM-CSF GENE, Flt3L-TRAIL FUSION GENE, shRNA INHIBITING TGF-BETA EXPRESSION, AND shRNA INHIBITING HSP EXPRESSION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
US6660257B1 (en) * 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
JP2007515946A (ja) 2003-06-13 2007-06-21 オンコマックス アクイジション コーポレイション 抗腫瘍二元機能融合タンパク質の調製および適用
ES2694180T3 (es) * 2012-01-20 2018-12-18 Vib Vzw Citocinas de haz alfa-helicoidal mutantes dirigidas
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017810A2 (en) * 1996-10-25 1998-04-30 G.D. Searle & Co. Multi-functional chimeric hematopoietic receptor agonists
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US20180360996A1 (en) * 2015-12-08 2018-12-20 University-Industry Foundation, Yonsei University ANTI-TUMOR COMPOSITION COMPRISING GM-CSF GENE, Flt3L-TRAIL FUSION GENE, shRNA INHIBITING TGF-BETA EXPRESSION, AND shRNA INHIBITING HSP EXPRESSION

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114606227A (zh) * 2022-02-22 2022-06-10 复旦大学 高精度腺嘌呤碱基编辑器及其应用
CN114606227B (zh) * 2022-02-22 2024-03-08 复旦大学 高精度腺嘌呤碱基编辑器及其应用

Also Published As

Publication number Publication date
WO2020198659A1 (en) 2020-10-01
EP3946409A4 (en) 2023-06-21
JP2025111546A (ja) 2025-07-30
CA3133830A1 (en) 2020-10-01
JP7749186B2 (ja) 2025-10-06
EP3946409A1 (en) 2022-02-09
US20220185857A1 (en) 2022-06-16
JP2022527322A (ja) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7729778B2 (ja) Ｆｍｓ様チロシンキナーゼ３（ｆｌｔ３）に対するキメラタンパク質およびキメラタンパク質複合体
EP3411398B1 (en) Targeted therapeutic agents and uses thereof
US12527843B2 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
JP2023082090A (ja) 自己免疫疾患の処置のためのサイトカイン抱合体
JP2025111546A (ja) Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質
WO2020257412A1 (en) Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
US20220056149A1 (en) Single-domain antibody-cytosine deaminase fusion proteins
US20230399406A1 (en) Targeted therapeutic agents and uses thereof
WO2015000585A1 (en) Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
JP7803927B2 (ja) Ｇｐ１３０結合分子および使用方法
HK40116401A (en) Targeted therapeutic agents and uses thereof
WO2026092701A1 (zh) 一种抗体-药物偶联物及其制备方法和用途
CN120917048A (zh) 达雷妥尤单抗药物偶联物及其制备

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination